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Abstract
Background: Animal model experiments have suggested a role of the DNA repair protein ERCC1 (Excision Repair
Cross-Complementation Group 1) in prostate cancer progression.
Methods: To better understand the impact of ERCC1 protein expression in human prostate cancer, a preexisting
tissue microarray (TMA) containing more than 12,000 prostate cancer specimens was analyzed by
immunohistochemistry and data were compared with tumor phenotype, PSA recurrence and several of the most
common genomic alterations (TMPRSS2:ERG fusions: deletions of PTEN, 6q, 5q, 3p).
Results: ERCC1 staining was seen in 64.7% of 10,436 interpretable tissues and was considered weak in 37.1%,
moderate in 22.6% and strong in 5% of tumors. High-level ERCC1 staining was linked to advanced pT stage, high
Gleason grade, positive lymph nodes, high pre-operative serum PSA, and positive surgical margin status (p < 0.0001
each). High ERCC1 expression was strongly associated with an elevated risk of PSA recurrence (p < 0.0001). This was
independent of established prognostic features. A subgroup analysis of cancers defined by comparable quantitative
Gleason grades revealed that the prognostic impact was mostly driven by low-grade tumors with a Gleason 3 + 3
or 3 + 4 (Gleason 4: ≤5%). High ERCC1 expression was strongly associated with the presence of genomic alterations
and expression levels increased with the number of deletions present in the tumor. These latter data suggest a
functional relationship of ERCC1 expression with genomic instability.
Conclusion: The results of our study demonstrate that expression of ERCC1 - a potential surrogate for genomic
instability - is an independent prognostic marker in prostate cancer with particular importance in low-grade tumors.
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Background
Prostate cancer is the most common cancer in males in
the western societies. While most patients will never suf-
fer symptoms from their disease, prostate cancer is still
the third most common cause of cancer related death of
men in most Western countries [1]. The highly variable
clinical course of the disease cannot be predicted reliably
enough by currently available criteria such as Gleason
grade, clinical stage and PSA value. Additional and bet-
ter prognostic markers are needed to differentiate be-
tween aggressive high risk and non-aggressive low risk
cancer subtypes in order to prevent unnecessary invasive
treatments.
The DNA repair endonuclease ERCC1 (Excision Repair
Cross-Complementation Group 1) catalyzes 5′ incision
during nucleotide excision repair process (NER) [2, 3].
ERCC1 has been described to be physiologically expressed
in several tissues including skin, breast, intestine, testis,
and ovary [4]. Overexpression of ERCC1 has been found
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in many cancer types such as urothelial carcinoma [5],
head and neck squamous cell carcinoma [6] and non-
small cell lung cancer [7]. For these entities it has been
proposed that ERCC1 overexpression may serve as a prog-
nostic and/or predictive tumor marker [5–9].
ERCC1 is of potential interest in prostate cancer. Ex-
perimental data from a mouse model system suggested
an altered ERCC1 function as potential driver for an in-
vasive prostate cancer phenotype [10]. Moreover, a spe-
cific nucleotide polymorphism of the ERCC1 gene was
linked to prostate cancer aggressiveness in a Spanish co-
hort study of 494 men [11]. The present study evaluates
the clinical impact of ERCC1 expression in human pros-
tate cancer. For this purpose, a preexisting prostate can-




Twelve thousand four hundred twenty seven prostatec-
tomy specimens were obtained from consecutive pa-
tients treated between 1992 and 2012 in the Department
of Urology and the Martini Clinics at the University
Medical Center Hamburg-Eppendorf. Tumor stage,
Gleason grade, nodal stage and the resection margin sta-
tus were recorded. Classical Gleason categories and
“quantitative” Gleason grading was performed as de-
scribed [12]. Follow-up data were available for a total of
12,344 patients (median 36 months, range 1 to
241 months; Table 1). Prostate specific antigen (PSA) re-
currence was defined as a postoperative PSA of ≥0.2 ng
/ ml and increasing. All prostate specimens were embed-
ded for histological analysis by a standard procedure
[13]. The TMA was produced as described [14, 15]. In
brief, one 0.6 mm core sample was taken from a repre-
sentative tissue block and distributed among 27 TMA
blocks, each with 144 to 522 samples. Each TMA block
contained various control and normal prostate tissue.
The molecular database attached to this TMA contained
results on ERG expression, ERG break apart FISH ana-
lysis [16], deletion status of 5q21 (CHD1) [17], 6q15
(MAP3K7) [18], PTEN (10q23) [19–21] and 3p13
(FOXP1) [22]).
Immunohistochemistry
Newly cut sections of the complete TMA were stained on
the same day in a single experiment. Slides were deparaffi-
nized and antigen was retrieved by heat (5 min at 121 °C,
pH 7.8 Tris-EDTA-citrate buffer). ERCC1 specific mouse
monoclonal antibody clone UMAB8, BioCAT GmbH,
Heidelberg; cat#UM500008; dilution 1:150) was applied at
37 °C for 60 min. Bound antibody was visualized with the
EnVision Kit (Dako, Glostrup, Denmark). ERCC1 typically
stained 100% tumor cell nuclei in a single tissue spot.
Staining intensity was assessed semi-quantitatively as
negative, weak, moderate and strong.
Statistics
Contingency tables were calculated to analyze associa-
tions between ERCC1 expression and clinico-
Table 1 Pathological and clinical data of the arrayed prostate
cancers
No. of patients (%)
Study cohort on








≤50 334 (2.7%) 81 (24.3%)
51–59 3061 (24.8%) 705 (23%)
60–69 7188 (58.2%) 1610 (22.4%)
≥70 1761 (14.3%) 370 (21%)
Pretreatment PSA (ng/ml)
<4 1585 (12.9%) 242 (15.3%)
4–10 7480 (60.9%) 1355 (18.1%)
10–20 2412 (19.6%) 737 (30.6%)
>20 812 (6.6%) 397 (48.9%)
pT stage (AJCC 2002)
pT2 8187 (66.2%) 1095 (13.4%)
pT3a 2660 (21.5%) 817 (30.7%)
pT3b 1465 (11.8%) 796 (54.3%)
pT4 63 (0.5%) 51 (81%)
Gleason grade
≤3 + 3 2848 (22.9%) 234 (8.2%)
3 + 4 6679 (53.8%) 1240 (18.6%)
3 + 4 Tert.5 433 (3.5%) 115 (26.6%)
4 + 3 1210 (9.7%) 576 (47.6%)
4 + 3 Tert.5 646 (5.2%) 317 (49.1%)
≥4 + 4 596 (4.8%) 348 (58.4%)
pN stage
pN0 6970 (91%) 1636 (23.5%)
pN+ 693 (9%) 393 (56.7%)
Surgical margin
Negative 9990 (81.9%) 1848 (18.5%)
Positive 2211 (18.1%) 853 (38.6%)
Percent in the column “Study cohort on TMA” refers to the fraction of samples
across each category. Percent in column “Biochemical relapse among
categories” refers to the fraction of samples with biochemical relapse within
each parameter in the different categories. NOTE: Numbers do not always add
up to 12,427 in different categories because of cases with missing data.
Abbreviation: AJCC, American Joint Committee on Cancer
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pathological parameters. Chi-square (Likelihood) test
was employed to identify significant relationships be-
tween these parameters. The F-test was used in analysis
of variance to detect differences of the mean of groups.
Kaplan-Meier curves were generated for the event of
PSA recurrence free survival and the log-Rank test was
applied to test for significant differences between strati-
fied survival curves. The prognostic significance of
pathological, molecular and clinical parameters was
assessed by Cox proportional hazards regression ana-
lysis. All calculations were done with JMP® software
(SAS Institute Inc., NC, USA).
Results
Technical issues
A total of 11,665 (93.9%) patients had follow up data
and 10,436 (84%) of samples were interpretable in the
TMA analysis (Table 1). Reasons for non-informative
cases were lack of tissue samples (1991 spots; 16%), ab-
sence of unequivocal cancer tissue in the TMA spot or
missing data.
ERCC1 immunohistochemistry
ERCC1 staining was negative or weak in basal and lu-
minal cells of normal prostate glands. Positive nuclear
ERCC1 staining was seen in 64.7% of 10,436 interpret-
able tissue samples, and was graded as weak in 37.1%,
moderate in 22.6%, and strong in 5% of tumors.
Representative images of ERCC1 immunohistochemistry
in prostate cancer samples are shown in Fig. 1. Strong
ERCC1 staining was linked to advanced pT stage, high
Gleason grade, positive lymph nodes, high pre-operative
serum PSA measurement, and positive surgical margin
status (p ≤ 0.0078; Table 2).
Association with TMPRSS2:ERG fusion status
ERCC1 expression was massively linked to the presence
of ERG expression and rearrangement. At least weak
ERCC1 staining was found in 85.4% of cancers with
immunohistochemically detected ERG expression and in
81.4% of tumors with ERG-rearrangement, but only in
52.6% (IHC) or 61.8% (FISH) of ERG-negative cancers
(p < 0.0001 each, Fig. 2). ERCC1 staining was similarly
linked to unfavorable tumor phenotype in subsets of
both ERG-negative and ERG-positive cancers (Add-
itional file 1: Tables S1 and S2).
Associations with key genomic changes of prostate
cancer
Chromosomal deletions represent the most frequent
genomic changes in prostate cancer next to
TMPRSS2:ERG fusion. To study whether ERCC1 expres-
sion might be particularly linked to any of the most
common deletions, ERCC1 data were compared to pre-
existing findings on 10q23 (PTEN), 3p13 (FOXP1), 6q15
(MAP3K7) and 5q21 (CHD1) deletions (Fig. 3). These
Fig. 1 Representative pictures of a) negative, b) weak, c) moderate and d) strong ERCC1 staining in prostate cancer
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analyses showed that ERCC1 expression was strongly
linked to all examined deletions. This was particularly
evident for ERG negative carcinomas (Fig. 3b) and only
marginally visible in ERG positive carcinomas (Fig. 3c).
Moreover, the level of ERCC1 expression was also
related to the number of deletions found in all cancer
(deletion load, Fig. 4; p < 0.0001). This held true also in
the subset of ERG-negative and ERG-positive cancers
(p < 0.0001; data not shown).
Association with cell proliferation
High levels of ERCC1 staining were significantly linked
to increased tumor cell proliferation measured as Ki67
labeling index (Ki67LI) (Table 3, p < 0.0001). This asso-
ciation held also true in almost all subgroups of cancers
with identical Gleason grade (≤3 + 3; 3 + 4; 4 + 3;
p < 0.0001 each).
Associations with prostate-specific antigen recurrence
The prognostic impact of pT stage (Fig. 5a), trad-
itional Gleason grade (Fig. 5b), and quantitative
Gleason grade (Fig. 5c) were strongly linked to PSA
recurrence. There was a significant association be-
tween high ERCC1 staining levels and early PSA re-
currence (p< 0.0001; Fig. 5d). This held also true for
the subgroups of ERG-negative (p< 0.0001; Fig. 5e)
and ERG-positive (p< 0.0001; Fig. 5f ) cancers. Analyz-
ing subsets of tumors with comparable traditional and
Table 2 Association between ERCC1 staining results and prostate cancer clinical characteristics
ERCC1 (%)
Parameter n evaluable Negative Weak Moderate Strong p value
All cancers 10,436 35.4 37.1 22.6 5.0
Tumor stage
pT2 6790 38.4 37.3 20.1 4.2 <0.0001
pT3a 2299 31.6 35.5 26.4 6.6
pT3b-pT4 1308 26.4 38.8 28.5 6.3
Gleason grade
≤3 + 3 2363 46.3 34.2 16.5 3.0 <0.0001
3 + 4 5630 34.7 37.4 22.9 5.0
3 + 4 Tert.5 368 33.4 40.8 22.0 3.8
4 + 3 1040 25.6 38.8 28.4 7.3
4 + 3 Tert.5 563 23.4 40.0 29.1 7.5
≥4 + 4 466 25.8 38.2 29.0 7.1
Lymph node metastasis
N0 5856 32.7 37.6 23.9 5.8 0.0037
N+ 585 25.6 39.8 27.9 6.7
Preoperative PSA level (ng/ml)
<4 1293 32.6 40.5 21.9 4.9 0.0078
4–10 6256 35.2 37.8 22.1 4.8
10–20 2058 37.5 33.9 23.5 5.1
>20 714 35.6 33.9 24.8 5.7
Surgical margin
Negative 8294 36.1 37.5 21.8 4.7 <0.0001
Positive 1953 32.7 35.5 25.9 5.9
Fig. 2 Positive ERCC1 staining correlates with ERG staining in
immunochemistry or ERG breakage in fluorescence in situ
hybridization (FISH)
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quantitative Gleason grades revealed that ERCC1 ex-
pression measurement did not provide very much
additional prognostic impact in morphologically char-
acterized tumor sets. Significant associations with
PSA recurrence were seen in Gleason 3 + 3 = 6
(p = 0.061), Gleason 3 + 4 (p = 0.0021) and 4 + 3
carcinomas (p = 0.0494) but not in tumors with a
Gleason ≥4 + 4 (Fig. 6a). A further refined subgroup
analysis by quantitative Gleason grading showed that
high ERCC1 expression identified cancers with worse
outcome only in those 3 + 4 carcinomas with a min-
imal fraction of Gleason 4 (≤5%) (Fig. 6b;
p = 0.0004). None of the other groups with a com-
parable quantitative Gleason grade showed outcome
differences according to the ERCC1 status (Fig. 6c-f ).
Multivariate analysis
Four different scenarios were tested. All these analyses
were also done in the ERG-negative and ERG-positive
subset (Table 4). Scenario 1 used the post-operatively
available parameters (pathological tumor stage (pT),
lymph node status (pN), surgical margin status, pre-
operative PSA value and classical Gleason grade). In Sce-
nario 2 the nodal status was dropped to reduce missing
data as lymph node dissection is not yet standardized in
radical prostatectomy. Scenario 3 included ERCC1 ex-
pression, pre-operative PSA, clinical tumor stage (cT
stage) and Gleason grade obtained on the prostatectomy
specimen. Since post-operative determination of a tu-
mors Gleason grade is more precise than the preopera-
tively determined Gleason grade [23], scenario 4 was
Fig. 3 Association between positive ERCC1 staining and 10q23 (PTEN), 5q21 (CHD1), 6q15 (MAP3K7), and 3p13 (FOXP1) deletion in a) all cancers,
b) the ERG-negative and c) ERG-positive subset
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added to better model the pre-operative situation. Here,
the pre-operative biopsy Gleason grade was combined
with pre-operative PSA, cT stage and ERCC1 expression.
Overall, these scenarios suggest a relevant role of ERCC1
expression as a prognostic factor, which tended to be -
especially in the pre-operative setting - independent of
established factors (scenario 3 and 4).
Discussion
In this study increased expression of the DNA repair
factor ERCC1 was identified as a strong prognostic
marker in prostate cancer, in particular for low-grade tu-
mors. Under the selected experimental conditions, de-
tectable ERCC1 staining was found in 65% of prostate
tumors. ERCC1 expression was virtually not detected in
normal prostate epithelium. This finding suggests an up-
regulation of ERCC1 during tumor development in a
proportion of prostate cancers. So far, comprehensive
studies on ERCC1 expression in clinical prostate cancer
samples are lacking. However, high-level ERCC1 expres-
sion has been reported from the prostate cancer cell
lines DU-145 and LNCaP [24]. Also, the 12 prostate
cancer samples, included in the Human Protein Atlas,
showed ERCC1 staining in 83–100% of cases depending
on the antibody used [25].
The strong association of elevated ERCC1 expression
with adverse morphological and clinical features of pros-
tate cancer found in this study, argues for a role of ERCC1
overexpression/activation in prostate cancer progression.
This assumption is supported by findings in other cancer
types where associations between high ERCC1 expression
levels and reduced overall survival had been found. This,
for example, includes reports on NSCLC as well as in gas-
tric and pancreatic cancers [7, 9, 26].
The large number of samples in this TMA and the as-
sociated database with numerous molecular features
allowed us to draw conclusions on the mechanistic role
of ERCC1 in prostate cancer. ERCC1-mediated endonu-
cleolytic incision and homologous recombination (HR)
have been implicated in the repair of DNA-interstrand
crosslinks (ICLs) which induce a potent replication block
followed by formation and repair of double strand
breaks (DSBs) [27]. Defective DSB repair and faulty
DNA replication are thought to be involved in the gen-
eration of chromosomal aberrations commonly seen in
cancer cells [28]. The striking association found between
elevated ERCC1 expression and chromosomal deletions
as well as with a positive ERG status is suggestive of a
link between ERCC1 activation and presence of chromo-
somal damage. ERCC1 may thus represent a surrogate
for genomic instability in proliferative active prostate
cancer cells. This hypothesis is further supported by the
continuous increase of ERCC1 levels with the number of
deletions detected, suggesting high level activity of repli-
cation associated DNA damage repair mechanisms in
subsets of prostate cancer with generation of chromo-
somal aberration via DSB formation and faulty repair.
TMPRSS2:ERG fusions were most strikingly linked to
ERCC1 expression. The reason for this particular strong
Fig. 4 Association between positive ERCC1 staining and number of
deletions in the ERG-positive subset
Table 3 Association between ERCC1 expression and Ki67-
labeling index in all, low- grade and high-grade prostate
cancers
Gleason grade ERCC1 n Ki67 LI (mean ± SD) p value
All grades Negative 2189 1.94 ± 0.06 <0.0001
Weak 2210 2.95 ± 0.06
Moderate 1422 3.38 ± 0.07
Strong 319 4.02 ± 0.14
≤3 + 3 Negative 672 1.68 ± 0.08 <0.0001
Weak 471 2.46 ± 0.09
Moderate 233 3.04 ± 0.13
Strong 44 2.77 ± 0.31
3 + 4 Negative 1200 1.89 ± 0.07 <0.0001
Weak 1308 2.86 ± 0.06
Moderate 866 3.27 ± 0.08
Strong 190 3.70 ± 0.17
4 + 3 Negative 241 2.51 ± 0.22 <0.0001
Weak 342 3.57 ± 0.18
Moderate 240 3.87 ± 0.22
Strong 65 4.98 ± 0.42
≥4 + 4 Negative 62 3.79 ± 0.56 0.05
Weak 80 4.8 ± 0.49
Moderate 74 4.28 ± 0.51
Strong 19 6.89 ± 1.01
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association remains unclear. Earlier studies had not im-
plicated ERCC1 as a gene that is directly regulated by
the transcription factor ERG [29–31]. The association
between deletions and ERCC1 expression was less clear
in ERG positive than in ERG-negative cancers, which is
likely due to the (already) markedly elevated levels of
ERCC1 in ERG-positive tumors. In case of additional de-
letions, this may not allow for a further elevation meas-
urable under the experimental conditions applied in this
study. The observed strong association between high
levels of ERCC1 and rapid tumor cell proliferation, as de-
termined by the Ki67 labeling index, is consistent with the
involvement of ERCC1 in the repair of replication associ-
ated DNA damage [32] as rapidly proliferating cancer cells
are subjected to high replication stress [33, 34].
ERCC1 was an independent predictor of poor outcome
in most multivariate analyses suggesting a strong clinical
utility of ERCC1 measurement. Remarkably, the analysis
of the prognostic role of ERCC1 expression in subgroups
of prostate cancer that were narrowly defined by
Fig. 5 Prostate specific antigen (PSA) recurrence free survival correlates with a) pathological stage, b) classical Gleason grade, c) quantitative
Gleason grade, and ERCC1 expression in d) all cancers, e) the ERG-fusion negative and f) positive subset
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identical quantitative Gleason grades suggested a limita-
tion of the prognostic value of ERCC1 measurement to
the earliest lesions, i.e. Gleason 3 + 3 or 3 + 4 with only
minimal (≤5%) Gleason 4 fraction. This limitation of the
prognostic impact to these subgroups is not a disap-
pointment as these tumors are subject to the most diffi-
cult therapeutic decision making with options ranging
from active surveillance to prostatectomy. That ERCC1
expression failed to provide prognostic information in
most subgroups in cancers with comparable quantitative
Gleason findings also demonstrates how high the bar lies
for prognostic molecular tests in prostate cancer. The
Gleason grading system is purely based on the simple
distinction of architectural features, neglects any cyto-
logical criteria, but is extremely powerful. The prognos-
tic power of the Gleason grade is much higher than the
histologic grading in various other cancer types, such as
for example kidney cancer [35] or invasive bladder
Fig. 6 Limited prognostic impact of ERCC1 expression in cancers grouped by a) classical and b-f) quantitative Gleason score. The quantitative
Gleason score is defined by the percentage of Gleason 4 patterns. Black dotted line denotes Gleason score category result, red line negative and
blue line strongly positive ERCC1 cancers within the respective category
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cancer [36]. This holds true if the Gleason grading
method is limited 5 prognostic subgroups [37]. Based
on the analysis of a cohort of more than 10,000 pros-
tate cancers available at our institution, we had re-
cently shown, that using the percentage of Gleason 4
grades as a continuous variable could expand Gleason
Grade information. Both in biopsies and in prostatec-
tomy samples, prostate cancer prognosis deteriorates
gradually with increasing percentage of Gleason 4 pat-
tern (quantitative Gleason Grade) [12]. Given the high
impact of pure morphologic information in prostate
cancer, we believe that a further improvement of
morphologic assessment going beyond architecture
and also involving digital image analysis and deep
machine learning will play a very important role in
prostate cancer assessment in the future.
Conclusions
In summary, elevated expression of ERCC1 is
strongly linked to unfavorable tumor phenotype and
PSA recurrence in prostate cancer. In this study, an
association between ERCC1 overexpression and
chromosomal aberrations (including both ERG fusion
and deletions) was observed. These findings suggest
overexpression of ERCC1 in the context of replica-
tion associated DNA damage repair, genomic in-
stability and generation of structural chromosomal
alterations.
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All cancers 1 5644 0.0009 <0.0001 - <0.0001 - <0.0001 0.0008 0.0746
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3 9062 <0.0001 - <0.0001 <0.0001 - - - 0.0045
4 8926 <0.0001 - <0.0001 - <0.0001 - - <0.0001
ERG-negative
subset
1 2829 <0.0001 <0.0001 - <0.0001 - 0.0001 0.0846 0.1110
2 4471 <0.0001 <0.0001 - <0.0001 - - 0.0002 0.0184
3 4432 <0.0001 - <0.0001 <0.0001 - - - 0.0526
4 4368 <0.0001 - <0.0001 - <0.0001 - - <0.0001
ERG-positive
subset
1 2242 0.0057 <0.0001 - <0.0001 - 0.0763 0.0092 0.0626
2 3584 <0.0001 <0.0001 - <0.0001 - - <0.0001 0.0613
3 3506 <0.0001 - <0.0001 <0.0001 - - - 0.0746
4 3451 <0.0001 - <0.0001 - <0.0001 - - 0.0009
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